Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYVIBE-006 in unresectable stage III non-small cell lung cancer
2022-502752-31-00Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 29
01
Overview
Phase 4, randomised, open-label trial of vibostolimab + pembrolizumab and durvalumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoint: No primary endpoint defined. Started Sep 2023; status: completed.
02
Drugs
vibostolimab + pembrolizumabdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-502752-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502752-31-00.